about
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusHemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosisFibroscan (transient elastography) for the measurement of liver fibrosisHelicobacter pylori moves through mucus by reducing mucin viscoelasticity.Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.Viscoelastic properties and dynamics of porcine gastric mucin.Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.Role of epoetin alfa in maintaining ribavirin dose.Use of growth factors with antiviral therapy for chronic hepatitis C.Introduction: thrombocytopenia in chronic liver disease -- treatment implications and novel approaches.Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection.Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.Thrombocytopenia associated with chronic liver disease.Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.Eltrombopag in patients with chronic liver disease.Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.Diffusion behavior of lipid vesicles in entangled polymer solutions.Liver cirrhosisTelaprevir for previously treated chronic HCV infection.IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells.A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary systems.Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practiceCirculating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis CRegression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease.Response-guided telaprevir combination treatment for hepatitis C virus infectionSofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.Diagnosis and quantitation of fibrosis.Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseVariants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionSilymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis CInterferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 yearsNatural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C
P50
Q28279955-07938340-E514-4F2F-86E6-29A669215021Q28569136-F7A9CF2B-B629-4474-BE90-3703BDD5C097Q30457466-ADE65AB6-F59D-469C-B92B-3D48B6240EA3Q30489798-EE77AE4C-4D2B-462A-9F5C-182795261FA9Q31019494-C5E696C8-EC52-472C-AD8D-7B12FB5488F4Q31170479-183D124B-694E-4F61-8E9B-EC28DC9CDBD3Q33316647-AEFB0F6A-9021-495E-B438-A5C01E39826EQ33360391-A2D57D65-424D-4631-87F5-2B60F1A1D11AQ33367339-9DB505FE-90B4-43F1-8C60-6791F2895D11Q33377122-2E7327C5-D108-4983-BA80-9C82EA1DD316Q33377131-9B35D298-2FA6-4E81-9C95-C133BA33F6E1Q33377599-4097C289-70CD-4A39-9D00-F16F2E6CDF90Q33379389-C63373A0-02EB-4EA9-8744-240B4DE1C40DQ33395929-AAFDE346-D2FC-4BCE-8739-5B6FB6779773Q33402924-0CF6C34D-8F3A-4E18-8588-0B1D3E09F960Q33406181-D03872C6-2284-4D56-B788-1B837E17AEEBQ33410939-56D77B2B-21B3-4F17-939C-28C9EF6110FBQ33421239-60D75031-6F3B-4204-AAE8-F92E39316D27Q33435950-7BD3EB83-9F04-4029-851C-4AD730BD2C81Q33907590-A9B5A287-13AC-41E8-BC39-26CE8A64CEB2Q34010340-53D19F18-71F0-467E-A153-C391EDDFB7ABQ34109057-EFBA82CA-C95E-424B-9E6B-A8883DDEBEAEQ34142463-4D7DB644-938E-4FA2-88C1-8E382BCF8341Q34146011-D6FB281C-4350-4065-868A-8C65060E0306Q34178705-BBA00CD2-F85D-447C-B8D6-9056BB945CCCQ34256062-4ED6DDD8-D3F2-4BC0-9C8D-2B88383CD689Q34271108-44B10774-4031-4FB1-B069-9A78DB6FED18Q34290930-D1273D63-9C54-443E-A133-8609FD6AE934Q34317204-0B54F3BB-DDEE-4059-9787-25F45713977FQ34322384-FB625E81-A126-4DAC-8ACC-9C8CC2E761FFQ34447506-21C60300-F2B8-4564-A18A-EEB301F98562Q34632295-E649D94B-07F5-4AD9-A4A8-B754CAE5F643Q34649453-65286B2C-2EBE-47E6-BCC1-FF68A425C3A6Q34777918-42E1132E-A111-4448-B222-92066E384DE2Q34867045-21FD1A91-5D19-4CD5-B722-33C6C0A4D43AQ34913385-4B5870D0-134F-4DDE-BC12-5DF7C8D24676Q34914880-DF14F961-0629-4AB7-9469-7ED56FE2EA76Q34974790-C3D62CC1-76CA-4DA9-A6F2-9707B10B36F1Q35288973-E67384D2-259B-4BC5-A927-97C5437B387FQ35508148-63BD5CA7-FFF1-4B28-BD69-761BE6BFA5C0
P50
description
researcher ORCID ID = 0000-0002-7342-6593
@en
name
Nezam Afdhal
@ast
Nezam Afdhal
@en
Nezam Afdhal
@es
Nezam Afdhal
@nl
type
label
Nezam Afdhal
@ast
Nezam Afdhal
@en
Nezam Afdhal
@es
Nezam Afdhal
@nl
prefLabel
Nezam Afdhal
@ast
Nezam Afdhal
@en
Nezam Afdhal
@es
Nezam Afdhal
@nl
P21
P31
P496
0000-0002-7342-6593